Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer
A phase 2 trial of Gemcitabine in pancreatic ductal adenocarcinoma, run by SynerGene Therapeutics, Inc., active and no longer recruiting.
Overview
Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer is a phase 2 interventional study registered as NCT02340117 by SynerGene Therapeutics, Inc., with 28 participants enrolled, started 2015-01 and due to reach its primary completion in 2026-12. Interventions recorded: SGT-53, nab-paclitaxel and Gemcitabine.
Similar pages
not linked directly; found by shared links- TrialIntra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialEvaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialClinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialPolymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialSafety and Performance of a Novel Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients With Pancreatic Cancer
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialA Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialIN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.